Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Frontiers in Public HealthOpen Access

Cost-effectiveness analysis of Chinese patent medicines for the treatment of postmenopausal osteoporosis in China

View Full Paper
Ask AI
Bookmark
Share

Authors

CWCong WangXLXihan LinJLJinyu Liu

Discussion

Loading...

Member takes

Overview

Cost-effectiveness analysis demonstrates effective treatment for postmenopausal osteoporosis with Chinese patent medicines, indicating strong economic viability.

Key Points

  • Preventive therapy using Chinese patent medicine significantly increased bone mineral density.
  • Incremental cost-effectiveness ratios for treatments were $11,955 per QALY at age 55 and $9,711 per QALY at age 74.
  • A Markov microsimulation model assessed cost-effectiveness for a hypothetical cohort of women aged 55 to 74.
  • Sensitivity analyses confirmed robustness, identifying the annual cost of the Jintiange capsule as the most sensitive factor.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68c1925e9b7b07f3a0617331https://doi.org/10.3389/fpubh.2025.1596676
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Jintiange combined with alfacalcidol improves muscle strength and balance in primary osteoporosis: A randomized, double-blind, double-dummy, positive-controlled, multicenter clinical trial2022 · 24 citations
  2. 2Incidence and cost of vertebral fracture in urban China: A five-year population-based cohort study2023 · 30 citations
  3. 3How Would You Manage This Patient With Osteoporosis?2018 · 9 citations
  4. 4Bone Health and Natural Products- An Insight2018 · 78 citations
  5. 5Evaluation of Impact on Health-Related Quality of Life and Cost Effectiveness of Traditional Chinese Medicine: A Systematic Review of Randomized Clinical Trials2012 · 38 citations